Introduction: Time-to-treatment-failure (TTF) is the interval from chemotherapy initiation to premature discontinuation. We evaluated TTF based on age.
Results: Among 1006 patients, 460 (46%) were older than 65 years of age. One hundred forty-five older patients (32% of this age cohort) completed all six planned chemotherapy cycles as did 170 (32%) younger patients. Median TTF was 2.9 months (95% confidence interval: 2.7-3.2) in older patients and 3 months (95% confidence interval: 2.9-3.5) in younger patients; adjustment for performance status and stratification by chemotherapy by trial yielded no statistically significant age-based difference in TTF. However, reasons for early chemotherapy cessation differed between age groups (multivariate p ¼ 0.004). Older patients were less likely to discontinue from cancer progression (41% versus 55%) and more likely from toxicity or patient choice (16% and 15%, respectively) compared to younger patients (13% and 6%, respectively). Older patients were more likely to experience grade 3þ adverse events (86% versus 79%) with no statistically significant difference in survival. An age cutpoint of 70þ years showed no difference in TTF, a lower trend of early cessation due to cancer progression, and somewhat shorter older patient survival.
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Introduction
Time-to-treatment failure (TTF) is the interval from initiation of chemotherapy to its premature discontinuation. Since early discontinuation can occur due to various reasons -such as cancer progression, adverse events, patient choice, or patient death -TTF can be influenced by factors unrelated to chemotherapy efficacy and is therefore seldom used for regulatory drug approval. 1 A compilation of endpoints from 144 consecutively published randomized controlled trials found that TTF ranked fifth in usage among six time-related endpoints, only ahead of time-to-tumor-response endpoint. 2 In older cancer patients, TTF can be an invaluable endpoint. TTF can potentially explain why multiple earlier studies show worse chemotherapy toxicity in older patients but comparable survival. [3] [4] [5] [6] [7] Older patients have well-documented, higher rates of severe adverse events, which can prompt the premature discontinuation of chemotherapy. Furthermore, many older patients may opt to transition to palliative care sooner. 8 Thus, comparing TTF between older patients and their younger counterparts is an important step in exploring treatment-related outcomes in geriatric oncology; it allows us to probe into the reasons for chemotherapy discontinuation, thereby potentially enabling us to intervene to make chemotherapy more tolerable, especially for older patients.
This study relied on a 1000þ-patient cohort to compare TTF in older versus younger patients and to better understand factors that contribute to comparative age-based reasons for the premature discontinuation of chemotherapy. This cohort consisted of patients who had been diagnosed with metastatic NSCLC, a malignancy associated with notable morbidity and a limited life expectancy and who were at risk for early discontinuation of chemotherapy for many reasons. This cohort provided a platform for understanding age-based duration of chemotherapy, reasons for stopping chemotherapy early, and associated outcomes.
Methods

Overview
Individual patient data from all arms of three, first-line, multi-institutional, prospectively conducted clinical trials from the Cancer and Leukemia Group B (CALGB), now the Alliance for Clinical Trials, were pooled. A deliberate decision was made to focus on NSCLC patients who were receiving conventional chemotherapy because these patients are at high risk for chemotherapy toxicity with a limited survival and because previous studies show that a finite number of initial conventional chemotherapy cycles is appropriate. 9 CALGB 9730, 30203, and 30801 were included. Patients had signed an institutional review boardapproved, protocol-specific informed consent in accordance with federal and institutional guidelines. These three trials had similar patient eligibility criteria that included 1) no prior chemotherapy, 2) stage IIIB/IV incurable NSCLC, and 3) Eastern Cooperative Oncology Group performance score of 0-2 and acceptable organ function. The only notable differences were that CALGB 9730 excluded patients with brain metastases or who were HIV positive whereas these patients were eligible for CALGB 30203 and 30801. The latter two trials excluded patients with cardiovascular events in the preceding 6 months; in both of these latter two trials, patients with chronic steroid or nonsteroidal antiinflammatory agent use must have had these agents discontinued 1 week before registration.
CALGB 9730 randomly assigned patients to receive carboplatin plus paclitaxel (carboplatin area under the curve [AUC] 6 mg/ml/min on day 1 and paclitaxel 225 mg/m 2 on day 1) versus paclitaxel alone. CALGB 30203 randomly assigned patients to carboplatin and gemcitabine (carboplatin AUC 5.5 mg/ml/min on day 1 and gemcitabine 1000 mg/m 2 on days 1 and 8) with or without zileuton or celecoxib. CALGB 30801 randomly assigned patients to carboplatin plus pemetrexed (carboplatin AUC 6 on day 1 and pemetrexed 500 mg/m 2 on day 1) for nonsquamous histology or carboplatin plus gemcitabine (carboplatin AUC 5.5 on day 1 with gemcitabine 1000 mg/m 2 on days 1 and 8) for squamous cell histology with or without celecoxib. [10] [11] [12] Patients in all three trials were to complete a maximum of 6 cycles of chemotherapy; these instructions were in keeping with findings from Socinski et al. 9 that discourage continuous chemotherapy of longer duration.
All three of these previously conducted clinical trials contributed to lung cancer therapeutics, concluding, respectively, that combination chemotherapy improves outcomes in age-unspecified patients, that the addition of a 5-lipoxygenase inhibitor (zileuton) does not improve outcomes, and that the addition of a COX-2 inhibitor (celecoxib) to chemotherapy in a population selected for COX-2 expression also does not improve outcomes. Individual patient data from these three trials were used in the current study with the goal of examining agebased TTF, reasons for the early discontinuation of chemotherapy, and other clinically germane outcomes, such as adverse event rates and overall survival.
Definition of Endpoints
The primary endpoint was TTF. Treatment failure was defined as chemotherapy discontinuation before completion of the planned 6 cycles for any reason, including cancer progression, adverse events, patient choice, or death. Secondary endpoints were chosen to probe into reasons behind premature chemotherapy discontinuation, specifically, cancer progression versus all other reasons. During the conduct of each trial, the health care team had reported on each patient's reasons for premature discontinuation. Because previous studies had reported higher rates of adverse events in older as opposed to younger patients and because adverse events were anticipated to be a major reason for chemotherapy discontinuation, age-based adverse event rates were selected as another secondary outcome. Finally, overall survival was also evaluated as a secondary outcome to provide context to the above endpoints and because survival is regarded as one of the most meaningful clinical outcomes in cancer care. 13 
Statistical Analyses
Two sets of analyses were conducted; the main set used an age cutpoint of 65 years and the other an age cutpoint of 70 years. Unless otherwise reported, conclusions from analyses based on these age cutpoints were similar. For the primary study endpoint, TTF is defined as the time from trial registration to treatment discontinuation or last follow-up. The event was discontinuation of chemotherapy for any reason other than completion of 6 cycles. The cumulative incidence of premature chemotherapy discontinuation was estimated separately by age group using the cumulative incidence function, treating chemotherapy completion as the competing risk. TTF was compared between age groups using the Cox proportional hazards model with age as the main effect and was adjusted for potential confounding baseline factors using a model selection procedure. Baseline factors including sex, performance status, smoking history, tumor histology, cancer stage, and chemotherapy by trial (paclitaxel alone in CALGB 9730 versus paclitaxel þ carboplatin in CALGB 9730 versus CALGB 30203 versus CALGB 30801 to account for potential differences in outcomes based on chemotherapy regimen and time era) were considered in the model building. Variables that reached the 0.05 significance level were kept in the final model. The proportional hazards assumption was tested for all variables. The frequencies of various reasons for chemotherapy discontinuation (cancer progression versus toxicity versus death versus all other reasons) as well as grade 3 or worse adverse events were summarized separately by age group and were compared between age groups using a chi-square test or the Fisher exact test, as appropriate. Overall survival was summarized by age group using the Kaplan-Meier estimator and compared using Cox regression models as described for TTF. Two-way interactions between age and other significant variables that remained in the model were evaluated; none were found to be statistically significant.
Analyses were conducted using SAS, version 9.4 on a dataset locked May 15, 2017. Data collection, analyses, and quality assurance was performed by the Alliance Statistics and Data Center and by the study chairperson following Alliance policies.
Results
Demographics
A total of 1006 patients comprise the cohort from all three trials. [10] [11] [12] Four hundred sixty patients (46%) were 65 years of age or older at trial enrollment, and 546 (54%) were younger than 65 years of age; 270 (27%) patients were 70 years of age or older. The age distributions were similar across the three trials. Patients had an Eastern Cooperative Oncology Group performance status of 2 or better; all had normal organ and marrow function at trial enrollment. Demographics appear in Table 1 .
TTF
Approximately 30% (315 of 985 patients, TTF was missing for 21 patients) of patients across all age groups completed the planned 6 cycles; 70% (670 of 985 patients) discontinued prematurely. One hundred forty-five patients who were 65 years of age or older (32% of 452 of this age cohort) completed all 6 cycles of chemotherapy, whereas 170 of 533 (32%) younger patients did the same. With a cutpoint of 70 years, the number of older and younger patients were 78 of 265 (29%) and 237 of 720 (33%), respectively.
Based on the cutpoint of 65 years, 302 of 452 (67%) premature chemotherapy discontinuation events occurred in patients 65 years of age or older, and 347 of 533 (65%) in younger patients. The median TTF was 2.9 months (95% confidence interval [CI]: 2.7-3.2 months) in patients 65 years of age or older and 3 months (95% CI: 2.9-3.5 months) in younger patients (Fig. 1) . Using the cutpoint of 70 years, 186 of 265 (70%) of older patients and 463 of 720 (64%) discontinued chemotherapy prematurely. The median TTF was 2.7 months (95% CI: 2.4-3.0 months) in patients 70 years of age or older and 3.2 months (95% CI: 3.0-3.5 months) in younger patients (Fig. 1) .
In the multivariate analysis, performance status was the only baseline factor that attained a significance level to merit inclusion in the final model. With adjustment for performance status and with stratification by chemotherapy by trial (categorized as CALGB 9730 paclitaxel alone versus CALGB 9730 paclitaxel þ carboplatin versus CALGB 30203 versus CALGB 30801, which did not meet the proportional hazards assumption -in this context, it means that our model did not assume that the relative risks of treatment failure among types of chemotherapy were constant over time), no statistically significant difference in TTF was observed based on age; comparisons between patients 65 years of age or older versus younger generated a hazard ratio (HR) of 1.060 (95% CI: 0.908-1.238; p ¼ 0.46). Poorer performance status was associated with a higher risk of premature chemotherapy discontinuation. Age-based comparison with an age cutpoint of 70 years confirmed this finding (HR ¼ 1.156; 95% CI: 0.97-1.37; p ¼ 0.10).
Premature Discontinuation of Chemotherapy and Underlying Descriptive Reasons
Descriptive reasons for the premature discontinuation of chemotherapy varied in frequency based on age groups (Table 2) . Cancer progression was the most common reason. In older patients, 41% (123 of 302 patients) discontinued chemotherapy due to cancer progression, 16% (49 of 302 patients) due to chemotherapy toxicity, 13% (40 of 302 patients) related to death, 15% (45 of 302 patients) as per patient choice, and 15% (45 of 302 patients) due to other reasons. In younger patients, 55% (189 of 347 patients) discontinued chemotherapy because of cancer progression, 13% (44 of 347 of patients) due to toxicity, 11% (39 of 347 patients) related to death, 6% (22 of 347 patients) as per patient choice, and 15% (53 of 347 patients) due to other reasons. In the multivariate analysis, adjusting for performance status and stratifying by chemotherapy by trial, the risk of early chemotherapy discontinuation due to cancer progression was lower in older patients compared to younger ones: HR ¼ 0.72; 95% CI: 0.57-0.90; p ¼ 0.004). Age-based comparison with an age cutpoint of 70 years showed a similar trend (HR ¼ 0.79; 95% CI ¼ 0.61-1.02; p ¼ 0.07).
Grade 3þ Adverse Events and Overall Survival
A higher percentage of older patients experienced grade 3 or worse adverse events, with 395 of 460 (86%) older patients compared to 429 of 546 (79%) younger patients. After adjusting for chemotherapy by trial, tumor histology, and performance status, the OR of developing a severe adverse event (grade 3-5) was higher in older patients at 1.77 (95% CI: 1.24-2.51; p ¼ 0.0015).
In patients 65 years of age or older, the median overall survival was 8.5 months (95% CI: 7.7-9.8), and in younger patients 9.9 months (95% CI: 8.7-11.1). In (17) 80 (15) 46 (17) 110 (15) (8) 19 (4) 19 (8) 34 (5) a Percentages may not sum to 100% because of either missing data or rounding.
July 2018 Time-to-Treatment-Failure and Related Outcomesthe multivariable analysis, performance status did not meet the proportional hazards assumption and hence was included in the Cox model as a stratification factor. Other baseline variables that were retained in the final model include sex, tumor histology, cancer stage, chemotherapy by trial, and smoking status. After adjusting for these baseline factors and after stratifying by performance status, no statistically significant difference in overall survival was discernible (HR ¼ 1.08; 95% CI: 0.95-1.22; p ¼ 0.25) (Fig. 2) . Age-based comparison with a cutpoint of 70 years yielded conservatively comparable findings with admittedly somewhat shorter survival among older patients (HR ¼ 1.16; 95% CI: 1.00-1.34; p ¼ 0.04) (Fig. 2) .
Discussion
This study did not find statistically significant differences in TTF between older and younger patients, although admittedly TTF was overall short and toxicity notable. Although we had hypothesized that TTF would be shorter in older patients, such was not the case. Interestingly, this study did reveal other age-based differences in select outcomes. Although cancer progression was the most frequent reason for stopping chemotherapy (15) 53 (15) 25 (13) 73 (16) a Includes reasons only among the 302, 347, 186, and 463 patients who stopped chemotherapy within the above respective age groups before the completion of 6 cycles.
b
Includes also a small subgroup of patients who had long therapy delays that precluded timely completion of 6 cycles of chemotherapy. Figure 2 . Overall survival showed no statistically significant differences in age-based comparisons with a trend suggestive of diminished survival in patients 70 years of age or older. CI, confidence interval.
prematurely irrespective of age, younger patients were more likely to discontinue chemotherapy because of cancer progression. A higher percentage of older patients stopped chemotherapy because of adverse events or choice. These observations invite further investigation into how to make chemotherapy more tolerable and acceptable for patients, particularly for older patients. Although patients should not continue to receive chemotherapy in the face of cancer progression, adverse event profiles and unrealistic or inaccurate expectations for chemotherapy can be attenuated, could lead to a longer TTF, and thereby potentially improve clinical outcomes. First, with respect to adverse event profiles, the Cancer and Aging Research Group evaluated chemotherapy dose reductions in older cancer patients and observed that first-cycle dose reductions appeared to lead to similar adverse event rates when compared to younger patients who did not receive a dose reduction.
14 Such findings suggest an intervention as simple as reducing the dose of chemotherapy with the first cycle might lead to a favorable cascade of events: better chemotherapy tolerability, longer TTF, and improved survival, particularly in older cancer patients. Recent studies seem to endorse such an approach in older patients. [15] [16] [17] Secondly, older cancer patients choose to forego or stop chemotherapy for reasons that range from fear of adverse events to logistical challenges. 18 Although older patients must undoubtedly make personal decisions about chemotherapy, efforts to counsel patients on realistic expectations, to apply an initial dose reduction to improve tolerability as described above, and perhaps even to acquire resources to help with the more quotidian aspects of chemotherapy administration, such as transportation to the chemotherapy unit, might enable older patients to remain on chemotherapy for longer and thereby derive greater benefit. Future studies should consider testing educational and practical interventions to evaluate whether they improve clinical outcomes for older cancer patients. Such studies could favorably influence outcomes in as many as 20% of older patients who otherwise would have stopped chemotherapy prematurely.
The current study is especially important because few have evaluated the premature cessation of chemotherapy in older cancer patients. Studying a 500-patient cohort, Laurent et al. 19 observed that older patients were more likely to stop cisplatin-based chemotherapy for metastatic bladder cancer after two or fewer cycles and that this early cessation led to a higher 1-year mortality rate. As another example, Kim et al. 20 observed that within a cohort of 98 older patients, slightly more than 30% discontinued palliative chemotherapy after first-line treatment, and those who discontinued did not live as long. These two studies underscore the main strengths of the current study: a large sample size of more than 1000 patients and detailed, real time clinical information on reasons for TTF.
The current study also has limitations. First, the findings reported here were drawn from clinical trials, a fact that introduces patient selection bias. These findings might not pertain to all older cancer patients and might require confirmation among older cancer patients who had not been clinical trial participants and in other groups of cancer patients in general. Second, this study did not specifically focus on very old cancer patients, for whom we have little data here as well as in general. Future studies should perhaps strive to focus on the very old. Third, because we analyzed prospectively collected data, it is possible that other unrecognized confounding factors might have influenced our results. Such a possibility is not unique to the current study but should be acknowledged.
Finally, we focused on TTF in patients who received conventional chemotherapy -as opposed to targeted therapy and immunotherapy -but, nonetheless, our findings remain important and relevant. Despite the emergence of targeted therapy and immunotherapy for NSCLC, most patients with an advanced stage of this malignancy continue to be candidates for conventional, first-line chemotherapy. Importantly, some of these newer treatment approaches, such as immunotherapy, are now given in combination with chemotherapy, thus adding further to the relevance of the work presented here. [21] [22] [23] Moreover, shifting demographics with a growing population of older cancer patients also add to the impetus to study TTF in older cancer patients and prompt the need to study ways to allow older patients to remain on chemotherapy for longer and to tolerate it better.
